Supercharge Your Innovation With Domain-Expert AI Agents!

Biomarker for myeloma diagnosis, application of biomarker and myeloma diagnosis kit

A technology of biomarkers and diagnostic reagents, applied in the field of myeloma diagnostic kits, can solve the problems of complicated diagnosis, missed treatment time, difficult disease discovery and treatment, etc., and achieve high sensitivity and specificity.

Pending Publication Date: 2022-04-29
SHANGHAI TENTH PEOPLES HOSPITAL
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Because myeloma has no obvious symptoms in the early stage of the disease, it is difficult to detect and treat the disease in the early stage, thus missing the best time for treatment; at the same time, the high heterogeneity of myeloma itself makes the diagnosis of MM complicated, and it is difficult for patients and their families. cause a large economic burden

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker for myeloma diagnosis, application of biomarker and myeloma diagnosis kit
  • Biomarker for myeloma diagnosis, application of biomarker and myeloma diagnosis kit
  • Biomarker for myeloma diagnosis, application of biomarker and myeloma diagnosis kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1: NF-κB non-Rel subunit RPS3 is highly expressed in myeloma

[0036] This example proves that the NF-κB non-Rel subunit RPS3 is highly expressed in myeloma through the following specific experimental procedures. The specific experimental procedures are as follows:

[0037] 1.1 Data source

[0038] By selecting the myeloma research data in the database, the expression of NF-κB non-Rel subunit RPS3 in myeloma patients was analyzed. The data come from the data GSE5900 and GSE6477 of the GEO database of NCBI respectively, and the above two projects are research data of myeloma. Download the normalized data from the above two sources to the local, process the data through LOG2, and find the probe 208692_at corresponding to the RPS3 gene. Among them, the chip source of the project GSE5900 is Affy’s U133 chip, and the corresponding annotation information is GPL570-55999.txt; the source of the project GSE6477 chip is Affy’s U133A chip, and the corresponding annotatio...

Embodiment 2

[0045] Example 2: Myeloma diagnostic kit for detecting RPS3 mRNA level

[0046] This embodiment prepares a myeloma diagnostic kit, which includes: mRNA extraction reagents and RPS3 mRNA detection reagents, RPS3 mRNA detection reagents in this embodiment are specific primers and PCR reagents, etc., by extracting mRNA from the sample and qPCR to detect the RPS3 mRNA content in the samples. The specific process is as follows:

[0047] 2.1 Sample collection

[0048] Bone marrow biopsy samples were collected from confirmed MM patients (experimental group) and malnutrition anemia patients (control group) at the same time. The diagnostic criteria of MM refer to the "2021 Revised Edition of Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma".

[0049] 2.2 mRNA extraction and reverse transcription

[0050] Add 1 mL of Trizol (total RNA extraction reagent) to the collected biopsy specimens of MM patients to be detected and controls without myeloma, and extract tot...

Embodiment 3

[0065] Example 3: Myeloma diagnostic kit for quantitative detection of RPS3 protein

[0066] This embodiment prepares a myeloma diagnostic kit, said kit includes: protein extraction reagent and RPS3 protein detection reagent, RPS3 protein detection reagent in this embodiment is RPS3 antibody, through protein extraction and specific antigen in the sample - Quantitative detection of RPS3 protein content in samples by antibody immune response. The specific process is as follows:

[0067] 3.1 Sample collection

[0068] Bone marrow biopsy specimens from confirmed MM patients (experimental group) and malnutrition anemia patients (control group) at the same time period as well as cell lines of various types of MM (ARP-1, OCI-MY5, H929, U266, RPMI8226) were collected. Cell pellet (positive control), MM diagnostic criteria refer to the "Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma 2021 Revision".

[0069] 3.2 Protein detection (extraction, quantification, d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a biomarker for myeloma diagnosis, application of the biomarker and a myeloma diagnosis kit, the biomarker for myeloma diagnosis is NF-kappa B non-Rel subunit RPS3, and the amino acid sequence of the biomarker is as shown in SEQ ID No. 1 or SEQ ID No. 2. The biomarker RPS3 is highly expressed in the body of a myeloma patient, has significant difference in expression quantity compared with that of RPS3 of healthy and normal people, and can be effectively used for diagnosis of the myeloma patient; meanwhile, a corresponding myeloma diagnostic kit is developed according to the biomarker, myeloma can be effectively detected by detecting RPS3 expression and / or the mRNA level of RPS3, and the diagnostic kit has high sensitivity and specificity for myeloma diagnosis.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a biomarker for diagnosis of myeloma, its application and a diagnosis kit for myeloma. Background technique [0002] Multiple myeloma (Multiple Myeloma, MM), also known as plasma cell myeloma, is a hematologic malignancy originating from the B-cell lineage. The main pathological feature is the accumulation of malignant plasma cells in the bone marrow and the production of abnormal immunoglobulins, resulting in elevated levels of abnormal immunoglobulins detectable in blood or urine and decreased synthesis of normal immunoglobulins. Does not participate in the immune response and suppresses the adaptive immune system. Multiple myeloma is more common in middle-aged and elderly people, but it can occur at any age, and there are no obvious symptoms in the early stage of the disease. As myeloma progresses, it can lead to serious consequences, including recurrent infections, bo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G01N33/574C12N15/11C07K14/47
CPCC12Q1/6886G01N33/57407G01N33/57484C07K14/47G01N2333/47C12Q2600/166
Inventor 施菊妹陈格格高学洁冯麒麟吴晓松
Owner SHANGHAI TENTH PEOPLES HOSPITAL
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com